earnings
confidence high
sentiment positive
materiality 0.65
ResMed Q3 revenue up 12% to $864.5M; non-GAAP EPS $1.32, up 2% YoY
RESMED INC
2022-Q3 EPS reported
$3.97
revenue$2,663,390,000
- Revenue $864.5M (+12% YoY); constant currency growth 14%.
- GAAP diluted EPS $1.22 (up from loss of $0.54); non-GAAP diluted EPS $1.32 (+2%).
- Gross margin contracted 140 bps to 56.8%; non-GAAP gross margin contracted 150 bps to 58.1%.
- Board declared $0.42/share dividend, record May 12, payable June 16, 2022.
- CEO cites strong sleep/respiratory demand but supply chain disruptions limit ability to meet demand.